| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
|
J Mol Biol
|
2007
|
2.45
|
|
2
|
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
|
Arthritis Rheum
|
2013
|
2.06
|
|
3
|
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
|
Ann Rheum Dis
|
2011
|
1.91
|
|
4
|
Differential expression of chitinases identify subsets of murine airway epithelial cells in allergic inflammation.
|
Am J Physiol Lung Cell Mol Physiol
|
2006
|
1.44
|
|
5
|
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
|
Ann Rheum Dis
|
2011
|
1.37
|
|
6
|
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.
|
BMC Pulm Med
|
2011
|
1.10
|
|
7
|
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.
|
J Am Acad Dermatol
|
2010
|
1.08
|
|
8
|
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.
|
Ann Rheum Dis
|
2013
|
1.06
|
|
9
|
An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype.
|
J Pharm Biomed Anal
|
2013
|
0.80
|
|
10
|
Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.
|
Rheumatology (Oxford)
|
2013
|
0.77
|
|
11
|
Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies.
|
Mol Immunol
|
2004
|
0.76
|